Log In Sign up
The largest database of trusted experimental protocols

Dako dab chromagen

Manufactured by Agilent Technologies
Visit Supplier

Dako DAB chromagen is a chromogenic substrate used in immunohistochemistry (IHC) procedures. It provides a brown staining reaction when oxidized by the enzyme label, typically horseradish peroxidase (HRP), which is conjugated to the primary antibody. The intensity of the brown staining indicates the presence and relative abundance of the target antigen in the tissue sample.

Automatically generated - may contain errors

Lab products found in correlation

Biotinylated goat anti rabbit igg, by Vector Laboratories (12 mentions) Dako autostainer, by Agilent Technologies (11 mentions) Dako lsab2 streptavidin hrp, by Agilent Technologies (10 mentions) Thermo autostainer 360, by Thermo Fisher Scientific (3 mentions) Avidin d and biotin solutions, by Vector Laboratories (3 mentions) Proteinase k, by Agilent Technologies (2 mentions) Dako lsab2 streptavidin horseradish peroxidase, by Agilent Technologies (1 mentions) Biotinylated goat anti rabbit immunoglobulin g igg, by Vector Laboratories (1 mentions) Biotinylated goat αrabbit igg, by Vector Laboratories (1 mentions) Sigma citrate buffer, by Merck Group (1 mentions) Vector horseradish peroxidase streptavidin, by Vector Laboratories (1 mentions) Hematoxylin qs, by Vector Laboratories (1 mentions) Myc n262, by Santa Cruz Biotechnology (1 mentions)

Spelling variants of this product

DAB chromagen (31 citations) Dako DAB chromagen IHC kit (1 citations)

16 protocols using dako dab chromagen

1

Necropsy and Immunohistochemical Analysis of EBOV

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Necropsy was performed on all subjects. Tissue samples of all major organs were collected for histopathologic and immunohistochemical examination, immersion-fixed in 10% neutral buffered formalin, and processed for histopathology as previously described16 (link),17 (link). For immunohistochemistry, specific anti-EBOV immunoreactivity was detected using an anti-EBOV VP40 protein rabbit primary antibody (Integrated BioTherapeutics) at a 1:4000 dilution. In brief, tissue sections were processed for immunohistochemistry using the Dako Autostainer (Dako). Secondary antibody used was biotinylated goat anti-rabbit IgG (Vector Laboratories) at 1:200 followed by Dako LSAB2 streptavidin-HRP (Dako). Slides were developed with Dako DAB chromagen (Dako) and counterstained with hematoxylin. Non-immune rabbit IgG was used as a negative control. Liver, adrenal gland, and inguinal lymph nodes representative images were taken at 40×, and spleen taken at 20× from control animal 0805068 (A, E, H, and M) or treated animals 0902056 (B, F, J, and N), 1005445 (C, G, K, and O), and 1006421 (D, H, L, and P).
Thi E.P., Mire C.E., Lee A.C., Geisbert J.B., Zhou J.Z., Agans K.N., Snead N.M., Deer D.J., Barnard T.R., Fenton K.A., MacLachlan I, & Geisbert T.W. (2015). Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates. Nature, 521(7552), 362-365.
+ Open protocol
+ Expand
2

Immunohistochemical Detection of ZEBOV

Check if the same lab product or an alternative is used in the 5 most similar protocols
Necropsy was performed on all subjects. Tissue samples of all major organs were collected for histopathologic and immunohistochemical examination, immersion-fixed in 10% neutral buffered formalin, and processed for histopathology as previously described21 . For immunohistochemistry, specific anti-ZEBOV immunoreactivity was detected using an anti-ZEBOV VP40 protein rabbit primary antibody (Integrated BioTherapeutics, Inc.) at a 1:4000 dilution. In brief, tissue sections were processed for immunohistochemistry using the Dako Autostainer (Dako). Secondary antibody used was biotinylated goat anti-rabbit IgG (Vector Laboratories) at 1:200 followed by Dako LSAB2 streptavidin-HRP (Dako). Slides were developed with Dako DAB chromagen (Dako) and counterstained with hematoxylin. Nonimmune rabbit IgG was used as a negative control.
Mire C.E., Matassov D., Geisbert J.B., Latham T.E., Agans K.N., Xu R., Ota-Setlik A., Egan M.A., Fenton K.A., Clarke D.K., Eldridge J.H, & Geisbert T.W. (2015). Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature, 520(7549), 688-691.
+ Open protocol
+ Expand
3

Immunohistochemical Detection of LASV

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tissue sections were deparaffinized and rehydrated through xylene, graded ethanols, and then processed for IHC using the Thermo Autostainer 360 (ThermoFisher, Kalamazoo, MI). Slides were treated with Proteinase K for 5 min to unmask antigens (Dako, Carpenteria, CA #S3020) followed by sequential 15-min incubations with avidin D and biotin solutions (Vector, Burlingame, CA) to block endogenous biotin reactivity. Specific anti-LASV immunoreactivity was detected using an anti-LASV NP primary antibody (Zalgen Labs, Frederick MD #CLD4) at a 1:1,000 dilution for 60 min. Secondary antibody used was biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA #BA-1000) at 1:200 for 30 min followed by Horseradish Peroxidase Streptavidin, R.T.U (Vector) for 30 min. Slides were developed with Dako DAB chromagen (Dako, Carpenteria, CA #K3468) for 5 min and counterstained with hematoxylin for 30 s.
Cross R.W., Heinrich M.L., Fenton K.A., Borisevich V., Agans K.N., Prasad A.N., Woolsey C., Deer D.J., Dobias N.S., Rowland M.M., Lathigra R., Borrega R., Geisbert J.B., Garry R.F., Branco L.M, & Geisbert T.W. (2023). A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proceedings of the National Academy of Sciences of the United States of America, 120(34), e2304876120.
+ Open protocol
+ Expand
4

Immunohistochemical Analysis of Nipah Virus

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Necropsy was performed on all subjects. Tissue samples of all major organs were collected for histopathologic and immunohistochemical examination and were immersion-fixed in 10% neutral buffered formalin for at least 21 days in BSL-4. Subsequently, formalin was changed; specimens were removed from BSL-4, processed in BSL-2 by conventional methods and embedded in paraffin and sectioned at 5-μm thickness as previously described33 (link). Briefly, for IHC, specific anti-NiV immunoreactivity was detected using an anti-NiV N protein rabbit polyclonal primary antibody28 (link) (kindly provided by Dr Christopher Broder, Uniformed Services University of the Health Sciences, Bethesda, MD) at a 1:5,000 dilution for 30 min. The tissue sections were processed for IHC using the Dako Autostainer (Dako, Carpinteria, CA). Secondary antibody used was biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) at 1:200 for 30 min followed by Dako LSAB2 streptavidin-HRP (Dako) for 15 min. Slides were developed with Dako DAB chromagen (Dako) for 5 min and counterstained with haematoxylin for 1 min. Non-immune rabbit IgG was used as a negative staining control.
Satterfield B.A., Cross R.W., Fenton K.A., Agans K.N., Basler C.F., Geisbert T.W, & Mire C.E. (2015). The immunomodulating V and W proteins of Nipah virus determine disease course. Nature Communications, 6, 7483.
+ Open protocol
+ Expand
5

Immunohistochemical Detection of ZEBOV

Check if the same lab product or an alternative is used in the 5 most similar protocols
Necropsy was performed on all subjects. Tissue samples of all major organs were collected for histopathologic and immunohistochemical examination, immersion-fixed in 10% neutral buffered formalin, and processed for histopathology as previously described21 . For immunohistochemistry, specific anti-ZEBOV immunoreactivity was detected using an anti-ZEBOV VP40 protein rabbit primary antibody (Integrated BioTherapeutics, Inc.) at a 1:4000 dilution. In brief, tissue sections were processed for immunohistochemistry using the Dako Autostainer (Dako). Secondary antibody used was biotinylated goat anti-rabbit IgG (Vector Laboratories) at 1:200 followed by Dako LSAB2 streptavidin-HRP (Dako). Slides were developed with Dako DAB chromagen (Dako) and counterstained with hematoxylin. Nonimmune rabbit IgG was used as a negative control.
Mire C.E., Matassov D., Geisbert J.B., Latham T.E., Agans K.N., Xu R., Ota-Setlik A., Egan M.A., Fenton K.A., Clarke D.K., Eldridge J.H, & Geisbert T.W. (2015). Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature, 520(7549), 688-691.
+ Open protocol
+ Expand
6

Immunohistochemical Detection of Nipah Virus

Check if the same lab product or an alternative is used in the 5 most similar protocols
Necropsy was performed on all subjects. Tissue samples of all major organs were collected for histopathologic and immunohistochemical examination and were immersion-fixed in 10% neutral buffered formalin for at least 21 days in BSL-4. Subsequently, formalin was changed; specimens were removed from BSL-4, processed in BSL-2 by conventional methods and embedded in paraffin and sectioned at 5 μm thickness. For immunohistochemistry, specific anti-NiV immunoreactivity was detected using an anti-NiV N protein rabbit primary antibody (kindly provided by Dr. Christopher Broder) at a 1:5,000 dilution for 30 minutes. The tissue sections were processed for immunohistochemistry using the Dako Autostainer (Dako, Carpinteria, CA). The secondary antibody used was biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) at 1:200 for 30 minutes followed by Dako LSAB2 streptavidin-HRP (Dako) for 15 minutes. Slides were developed with Dako DAB chromagen (Dako) for 5 minutes and counterstained with hematoxylin for one minute. Non-immune rabbit IgG was used as a negative staining control.
Dong J., Cross R.W., Doyle M.P., Kose N., Mousa J.J., Annand E.J., Borisevich V., Agans K.N., Sutton R., Nargi R., Majedi M., Fenton K.A., Reichard W., Bombardi R.G., Geisbert T.W, & Crowe JE J.r. (2020). Potent henipavirus neutralization by antibodies recognizing diverse sites on Hendra and Nipah virus receptor binding protein. Cell, 183(6), 1536-1550.e17.
+ Open protocol
+ Expand
7

Profiling NMT1 and NMT2 Expression in Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
All human tissues were obtained after review and approval of our local research ethics committee, protocol ETH #25928. Tissue microarrays from participants in the BCIRG 001 clinical trial [16 (link)] were obtained. The TMA slides contained formalin-fixed paraffin embedded triplicate core tissue samples (1.0 mm in diameter) from each tumor pretreatment. 5 micron thick TMA slices were deparaffinized, rehydrated, and antigen retrieval performed with 0.05% citraconic anhydride epitope retrieval buffer (details in Supplementary Methods). Overnight primary antibody incubation with NMT1 mAb 6F8D5 (1:100) and the NMT2 mAb 6C5E8 (1:1000) was followed by Dako Envision + HRP labeled secondary antibody for 1 h at room temperature. Slides were then stained with Dako DAB + chromagen, 1% CuSO4, and haematolyxlin. Omitting primary antibody served as a negative control in all experiments.
Mackey J.R., Lai J., Chauhan U., Beauchamp E., Dong W.F., Glubrecht D., Sim Y.W., Ghosh S., Bigras G., Lai R, & Berthiaume L.G. (2021). N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target. Breast Cancer Research and Treatment, 186(1), 79-87.
+ Open protocol
+ Expand
8

Histopathological and IHC Analysis of Necropsy Tissues

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Necropsy was performed on all subjects. Tissue samples from major organs were collected for histopathological and IHC examination, immersion fixed in 10% neutral buffered formalin, and processed for histopathologic analysis as previously described [11 (link), 12 (link)]. For IHC analysis, specific anti-ZEBOV immunoreactivity was detected using an anti-ZEBOV VP40 protein rabbit primary antibody (Integrated BioTherapeutics) at a 1:4000 dilution. Tissue sections were processed for IHC analysis, using the Dako Autostainer (Dako). Secondary antibody used was biotinylated goat anti-rabbit immunoglobulin G (IgG; Vector Laboratories) at 1:200 followed by Dako LSAB2 streptavidin–horseradish peroxidase (Dako). Slides were developed with Dako DAB chromagen (Dako) and counterstained with hematoxylin. Nonimmune rabbit IgG was used as a negative control.
Mire C.E., Geisbert J.B., Agans K.N., Deer D.J., Fenton K.A, & Geisbert T.W. (2016). Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus. The Journal of Infectious Diseases, 214(Suppl 3), S263-S267.
+ Open protocol
+ Expand
9

Immunohistochemical Analysis of Nipah Virus

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Necropsy was performed on all subjects. Tissue samples of all major organs were collected for histopathologic and immunohistochemical examination and were immersion-fixed in 10% neutral buffered formalin for at least 21 days in BSL-4. Subsequently, formalin was changed; specimens were removed from BSL-4, processed in BSL-2 by conventional methods and embedded in paraffin and sectioned at 5 μm thickness as previously described [33 (link)]. Briefly, for immunohistochemistry, specific anti-NiV immunoreactivity was detected using an anti-NiV N protein rabbit polyclonal primary antibody [28 (link)] (kindly provided by Dr. Christopher Broder, Uniformed Services University of the Health Sciences, Bethesda, MD) at a 1:5000 dilution for 30 minutes. The tissue sections were processed for immunohistochemistry using the Dako Autostainer (Dako, Carpinteria, CA). Secondary antibody used was biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) at 1:200 for 30 minutes followed by Dako LSAB2 streptavidin-HRP (Dako) for 15 minutes. Slides were developed with Dako DAB chromagen (Dako) for 5 minutes and counterstained with hematoxylin for one minute. Non-immune rabbit IgG was used as a negative staining control.
Satterfield B.A., Cross R.W., Fenton K.A., Agans K.N., Basler C.F., Geisbert T.W, & Mire C.E. (2015). The immunomodulating V and W proteins of Nipah virus determine disease course. Nature Communications, 6, 7483.
+ Open protocol
+ Expand
10

Necropsy and Immunohistochemical Analysis of EBOV

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Necropsy was performed on all subjects. Tissue samples of all major organs were collected for histopathologic and immunohistochemical examination, immersion-fixed in 10% neutral buffered formalin, and processed for histopathology as previously described16 (link),17 (link). For immunohistochemistry, specific anti-EBOV immunoreactivity was detected using an anti-EBOV VP40 protein rabbit primary antibody (Integrated BioTherapeutics) at a 1:4000 dilution. In brief, tissue sections were processed for immunohistochemistry using the Dako Autostainer (Dako). Secondary antibody used was biotinylated goat anti-rabbit IgG (Vector Laboratories) at 1:200 followed by Dako LSAB2 streptavidin-HRP (Dako). Slides were developed with Dako DAB chromagen (Dako) and counterstained with hematoxylin. Non-immune rabbit IgG was used as a negative control. Liver, adrenal gland, and inguinal lymph nodes representative images were taken at 40×, and spleen taken at 20× from control animal 0805068 (A, E, H, and M) or treated animals 0902056 (B, F, J, and N), 1005445 (C, G, K, and O), and 1006421 (D, H, L, and P).
Thi E.P., Mire C.E., Lee A.C., Geisbert J.B., Zhou J.Z., Agans K.N., Snead N.M., Deer D.J., Barnard T.R., Fenton K.A., MacLachlan I, & Geisbert T.W. (2015). Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates. Nature, 521(7552), 362-365.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!